BIGG Rec Logo
BIGG Rec Logo

Bibliographic Info

GuidelineWHO consolidated guidelines on drug-resistant tuberculosis treatment
Year of Publication2019
Issuing InstitutionWorld Health Organization

Recommendation

Status
Maintained

Recommended in favor

Conditional

In multidrug-resistant TB or isoniazid-resistant, rifampicin-resistant TB patients on longer regimens, all three Group A agents and at least one Group B agent should be included to ensure that treatment starts with at least four TB agents likely to be effective, and that at least three agents are included for the rest of treatment after bedaquiline is stopped. If only one or two Group A agents are used, both Group B agents are to be included. If the regimen cannot be composed with agents from Groups A and B alone, Group C agents are added to complete it (Group A: fluoroquinolones (levofloxacin and moxifloxacin), bedaquiline and linezolid were considered highly effective and strongly recommended for inclusion in all regimens unless contraindicated.– Group B: clofazimine and cycloserine or terizidone were conditionally recommended as agents of second choice.– Group C: included all other medicines that can be used when a regimen cannot be composed with Group A and B agents. The medicines in Group C are ranked by the relative balance of benefit to harm usually expected of each)

Also Featured In

This recommendation also appears in the following guidelines:

Guideline

WHO consolidated guidelines on tuberculosis: Module 4: Treatment - Drug-resistant tuberculosis treatment

Year2020
InstitutionWorld Health Organization
Guideline

WHO consolidated guidelines on tuberculosis: Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update

Year2022
InstitutionWorld Health Organization
Guideline

WHO consolidated guidelines on tuberculosis: module 4: treatment and care

Year2025
InstitutionWorld Health Organization
Powered byEpistemonikos Foundation